Kadderum (Eltrombopag)

Eltrombopag binds to the thrombopoietin (c‑Mpl) receptor on megakaryocyte precursors, activating intracellular JAK‑STAT pathways. This stimulation promotes the growth and maturation of megakaryocytes, leading to increased platelet formation in the bone marrow.

The dosage of Kadderum is individualized. A qualified prescriber determines the appropriate dose based on the patient’s platelet count, underlying condition, and response to therapy. Patients should follow the prescribing clinician’s instructions without self‑adjusting the dose.

The pregnancy and lactation categories for eltrombopag are not definitively established. Use during pregnancy or while breastfeeding is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and should be decided by the treating physician.

To order Kadderum, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to eltrombopag is romiplostim, another thrombopoietin receptor agonist administered by injection. While both increase platelet production, eltrombopag is an oral agent, offering convenience, whereas romiplostim requires subcutaneous dosing. Efficacy and safety profiles differ slightly, and the choice depends on patient preference, clinical response, and physician judgment.

Kadderum should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the product from moisture and direct sunlight. Keep it out of reach of children and do not use if the packaging is damaged.

Kadderum is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow any specific instructions from their prescriber regarding timing relative to meals or other medications.

Serious risks include thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, severe liver injury, and rare cases of bone‑marrow fibrosis. Patients should report any new or worsening pain, swelling, jaundice, or unexplained bruising to their healthcare provider promptly.

Kadderum is contraindicated in patients with known hypersensitivity to eltrombopag or any excipients, and in individuals with active malignant disease where platelet stimulation could be harmful. Caution is also advised for patients with uncontrolled liver disease or a history of thrombotic disorders.